AXIM Biotechnologies, Inc. is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical and nutraceutical products. Utilizing proprietary delivery platforms designed to enhance bioavailability and consistency, the company seeks to address a range of therapeutic areas including pain management, neurological disorders and general wellness. AXIM’s research and development efforts center on scalable formulation technologies that allow for precise dosing of cannabinoids such as CBD and THC in oral, sublingual, transdermal and inhalable formats.
The company’s core portfolio includes self-emulsifying drug delivery systems (SEDDS) and microemulsion technologies that facilitate rapid absorption and improved stability. These delivery systems are applied across a variety of product categories, from softgel capsules and tinctures to topical creams and convenience formats like gummies and sprays. AXIM also leverages strategic partnerships and licensing agreements with academic and clinical research institutions to advance its pipeline through preclinical studies and human trials.
Founded in 2013 and headquartered in Playa Vista, California, AXIM Biotechnologies has expanded its footprint through targeted acquisitions and global distribution partnerships. Over time, the company has integrated botanical extraction, analytical testing and scalable manufacturing capabilities to support both bulk ingredient sales and finished-product lines. AXIM’s management team combines expertise in pharmaceutical development, regulatory affairs and commercial operations, with leadership spearheaded by CEO Frank Scuteri, a veteran in the biotech sector, and a board that includes professionals in clinical research and finance.
AXIM serves markets across North America, Europe and Latin America, pursuing regulatory approvals that align with evolving cannabinoid guidelines. By maintaining a vertically integrated approach—from proprietary research and formulation through to production and distribution—the company aims to meet stringent quality standards and position its brands for entry into both the medicinal and consumer wellness segments.
AI Generated. May Contain Errors.
Free AXIM Stock Alerts